United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Enlivex Therapeutics Ltd.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -55.95% | -2.34% | -2.39% | -2.45% | -2.51% | -2.58% |
|---|---|---|---|---|---|---|
| ROA | -46.54% | -1.97% | -1.97% | -1.97% | -1.97% | -1.97% |
| Total Assets | $27,687.00K | $27,687.00K | $27,687.00K | $27,687.00K | $27,687.00K | $27,687.00K |
| Net Income | -$15,014.00K | -$545.00K | -$545.00K | -$545.00K | -$545.00K | -$545.00K |